3
Orphan Designations
0 approved, 3 designated
0
FDA Approvals
1
Active Trials
200 recruiting
3
Rare Diseases
across 5 areas
0
News (30d)
Quiet
BioAtla LLC is a company with 3 orphan drug designations across 3 rare diseases. Active clinical trials in 1 indication.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| cancer | - | Des.TrialAppr. |
| malignant pancreatic neoplasm | humanized IgG1 antibody specifific for the AXL tyrosine kinase conjugated to monomethyl auristatin E | Des.TrialAppr. |
| soft tissue sarcoma | humanized IgG1anti-AXL-antibody conjugated to monomethyl auristatin Econditionally active biologics-anti-ROR2-antibody drug conjugate consisting of a humanized IgG1 antibody specific for ROR2 tyrosine kinase conjugated to a peptide linker coupled with monomethyl auristatin E | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
31
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
31
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
0
affecting portfolio